Headache & Migraine
Conference Coverage
Galcanezumab benefits patients with migraine and medication overuse
PHILADELPHIA – The monoclonal antibody effectively reduces the number of monthly migraine headache days and...
Guidelines
Pediatric, adolescent migraine treatment and prevention guidelines are updated
The guidelines review both pharmacologic and nonpharmacologic options, which have multiplied since the previous guidelines were released in 2004...
Conference Coverage
Ubrogepant shows acute migraine efficacy in triptan nonresponders
PHILADELPHIA – Data from two ubrogepant pivotal trials showed similar migraine pain relief in triptan-ineffective and triptan-effective patients...
Conference Coverage
Asthma hospitalization in kids linked with doubled migraine incidence
PHILADELPHIA – Data from 11 million U.S. pediatric inpatients showed a doubled rate of migraine diagnoses among kids hospitalized for asthma.
Conference Coverage
Lasmiditan is associated with driving impairment
PHILADELPHIA – Impairment is detected at 1.5 hours after dosing and is resolved by 8 hours after dosing.
Conference Coverage
Treatment of episodic cluster headache deviates from recommendations
PHILADELPHIA – Among patients with episodic cluster headache, use of acute medications is high, but use of...
Video
Quarterly intravenous eptinezumab prevents migraine
PHILADELPHIA – Results from a pair of dose-ranging, randomized studies showed one IV eptinezumab dose cut migraine recurrences for 3 months.
Conference Coverage
Efficacy of erenumab is sustained over more than 4 years of treatment
PHILADELPHIA – Among patients with episodic migraine, 4.5 years of preventive treatment with erenumab is effective, safe, and well tolerated,...
Conference Coverage
Posttraumatic headache may be associated with reduced pain thresholds
PHILADELPHIA – Symptoms of photophobia and allodynia are more severe in patients with posttraumatic headache,...
Conference Coverage
Exposure to patients with migraine increases likelihood of stigmatizing attitudes
PHILADELPHIA – An analysis of survey data raises questions about how to combat negative attitudes toward patients...
Conference Coverage
Atogepant shows safety, efficacy for migraine prevention
PHILADELPHIA – Atogepant is the first drug from its small-molecule class to undergo advanced clinical testing for migraine prevention.